Klamkin Jonathan sold $1.3M of ALMU (indirect holdings)
Klamkin Jonathan (Chief Executive Officer) sold 100,000 indirectly-held shares of Aeluma, Inc. (ALMU) at $13.35 ($1.34M total) on 2026-09-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, potentially affecting investor perception of confidence.
Market read
New insider sell adds modest negative sentiment for ALMU; limited broader market impact.
What to watch
The 10b5-1 plan pre-arranged sale may have been scheduled long before any material news.
Background
Form 4 filings disclose insider transactions; a CEO sale often draws investor attention.
Ticker impact
CEO Jonathan Klamkin sold 100,000 shares for $1.33M via a 10b5-1 plan, reducing his stake to 1,226,995 shares.
Possible modest downward pressure over the next few days.
Large insider sale by the CEO, disclosed via Form 4, often leads to negative market reaction, especially when no accompanying positive news.
Market effects
May raise concerns for the biotech/health sector if similar insider activity is observed.
Limited to US markets where ALMU trades.
Low, as the company is small-cap with limited global exposure.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- CompanyAeluma, Inc.
Biotech firm listed on NASDAQ under ticker ALMU.
- ExecutiveJonathan Klamkin
Chief Executive Officer of Aeluma, Inc.

